Literature DB >> 1693698

Antibody-mediated neutralization in vivo of infectious papillomaviruses.

N D Christensen1, J W Kreider.   

Abstract

Specific antibody-mediated neutralization of infectious human papillomavirus type 11 (HPV-11) was achieved in the athymic mouse xenograft system, in which HPV-11 induced morphological transformation of human foreskin. Virus-specific neutralization was demonstrated by the ability of an HPV-11-specific polyclonal antiserum to neutralize HPV-11 infectivity and not bovine papillomavirus type 1 (BPV-1) or cottontail rabbit papillomavirus (CRPV) infectivity. In all three virus infectivity systems, neutralization was detected by the failure of the virus suspension to induce morphological transformation of the appropriate skin xenografts placed under the renal capsule of athymic mice. Rabbit polyclonal antisera were also generated against intact virions of both BPV-1 and CRPV, and neutralizing activity was tested in the xenograft system with BPV-1 and fetal bovine skin and with CRPV and rabbit ear skin. The three polyclonal antisera contained virus-specific neutralizing antibodies, demonstrating that neutralizing epitopes existed on all three papillomaviruses and that these epitopes were antigenically non-cross-reactive. The athymic mouse xenograft system was a useful model for detecting papillomavirus-specific neutralizing antibodies and offers the only opportunity for the analysis of neutralizing antibodies to human papillomaviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693698      PMCID: PMC249518     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  12 in total

1.  STUDIES ON THE MECHANISM RESPONSIBLE FOR THE SPONTANEOUS REGRESSION OF THE SHOPE RABBIT PAPILLOMA.

Authors:  J W KREIDER
Journal:  Cancer Res       Date:  1963-10       Impact factor: 12.701

2.  Carcinoma of the larynx after irradiation for papilloma.

Authors:  T C GALLOWAY; G R SOPER; J ELSEN
Journal:  Arch Otolaryngol       Date:  1960-09

3.  Structural polypeptides of rabbit, bovine, and human papillomaviruses.

Authors:  M Favre
Journal:  J Virol       Date:  1975-05       Impact factor: 5.103

4.  Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins.

Authors:  N D Christensen; J W Kreider; N M Cladel; D A Galloway
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

5.  Proteins present in bovine papillomavirus particles.

Authors:  P M Larsen; L Storgaard; S J Fey
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

6.  Topographical and conformational epitopes of bovine papillomavirus type 1 defined by monoclonal antibodies.

Authors:  L M Cowsert; P Lake; A B Jenson
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

7.  Demonstration of in vitro synthesis of human papilloma viral proteins from hand and foot warts.

Authors:  S J Fey; T Nielsen; M Vetner; L Storgaard; V Smed; P M Larsen
Journal:  J Invest Dermatol       Date:  1989-06       Impact factor: 8.551

8.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

9.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  42 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; F Breitburd; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus.

Authors:  P Le Cann; A Touze; N Enogat; D Leboulleux; C Mougin; M C Legrand; C Calvet; J M Afoutou; P Coursaget
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 8.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.

Authors:  Joseph J Carter; Greg C Wipf; Sarah F Benki; Neil D Christensen; Denise A Galloway
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.